Jump to content

Olanzapine

From Wikipedia
olanzapine
type of chemical entity
Subclass ofatypical antipsychotic, heterocyclic compound Edit
Part ofresponse to olanzapine Edit
Get useMedication Edit
Stylized nameOLANZapine, ZyPREXA Edit
Tautomer ofolanzapine tautomer Edit
Chemical formulaC₁₇H₂₀N₄S Edit
Canonical SMILESCC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C Edit
Legal status (medicine)boxed warning Edit
Pregnancy categoryAustralian pregnancy category C, US pregnancy category C Edit

Olanzapine, dem sell under de brand name Zyprexa among odas, be an atypical antipsychotic dem primarily use to treat schizophrenia den bipolar disorder.[1] E sanso sam times be used off-label insyd cancer patients for treatment of chemotherapy-induced nausea den vomiting[2] den as an appetite stimulant.[3] For schizophrenia, e fi be used for both new-onset disease den long-term maintenance.[1] Dem dey take am by mouth anaa by injection into a muscle.[1]

Common side effects dey include feeling tired, dizziness, constipation, dry mouth, den restlessness.[1] Oda side effects dey include low blood pressure plus standing, allergic reactions, neuroleptic malignant syndrome, diabetes mellitus, seizures, den tardive dyskinesia.[1] Insyd older people plus dementia, ein use dey increase de risk of death.[1] Use insyd de later part of pregnancy fi result in a movement disorder insyd de baby for sam time after birth.[1] Although ein mechanism of action no be entirely clear, e be known to block dopamine den serotonin receptors.[1]

Dem patent olanzapine insyd 1991 wey dem approve am for medical use insyd de United States insyd 1996.[4][5] E be available as a generic medication.[4] Insyd 2023, na e be de 167th most commonly prescribed medication insyd de United States, plus more dan 3 million prescriptions.[6][7] E dey on de World Health Organization's List of Essential Medicines.[8]

References

[edit | edit source]
  1. 1 2 3 4 5 6 7 8 "Olanzapine, Olanzapine Pamoate Monograph for Professionals". Drugs.com. AHFS. Retrieved 24 December 2018.
  2. ↑ Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ (January 2019). "ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients". Supportive Care in Cancer. 27 (1): 87–95. doi:10.1007/s00520-018-4464-y. PMID 30284039.
  3. ↑ Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, Govindarajalou R, Kt H, Ganesan P (May 2023). "Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer". Journal of Clinical Oncology. 41 (14): 2617–2627. doi:10.1200/JCO.22.01997. PMID 36977285.
  4. 1 2 "Olanzapine, Olanzapine Pamoate Monograph for Professionals". Drugs.com. AHFS. Retrieved 24 December 2018.
  5. ↑ Taylor D, Paton C, Kapur S (2015). The Maudsley Prescribing Guidelines in Psychiatry (12th ed.). London, U K: Wiley-Blackwell. p. 16. ISBN 978-1-118-75460-3.
  6. ↑ "The Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
  7. ↑ "Olanzapine Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 12 August 2025.
  8. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
[edit | edit source]
Dem retrieve am from "https://gpe.wikipedia.org/w/index.php?title=Olanzapine&oldid=96999"